Monoclonal Antibody to Plasminogen Activator Inhibitor 1 (PAI1)
| Code | Size | Price |
|---|
| MAA532Hu23-20ul | 20ul | £85.00 |
Quantity:
| MAA532Hu23-100ul | 100ul | £158.00 |
Quantity:
| MAA532Hu23-200ul | 200ul | £213.00 |
Quantity:
| MAA532Hu23-1ml | 1ml | £486.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Plasminogen Activator Inhibitor 1
Potency (Clone Number):
D1
Reactivity:
Po;
Source:
Monoclonal antibody preparation
Usage:
Western blottin:g: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Plasminogen Activator Inhibitor 1 (PAI1) | RPA532Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||